Insulet Corporation Announces Pricing of Secondary Public Offering

Wednesday, November 7, 2007 General News J E 4
BEDFORD, Mass., Nov. 7 Insulet Corporation,(Nasdaq: PODD), the manufacturer and marketer of the OmniPod(R) InsulinManagement System, today announced the pricing of its public offering of4,898,398 shares of common stock at $23.25 per share, all of which are beingsold by selling stockholders. Insulet will not receive any proceeds from thesale of shares by the selling stockholders. Insulet has granted to theunderwriters an option to purchase up to 734,759 shares of its common stock atthe public offering price to cover any over-allotments.

J.P. Morgan Securities Inc. and Merrill Lynch, Pierce, Fenner & SmithIncorporated are acting as joint book-running managers, and Leerink Swann LLC,Thomas Weisel Partners LLC and Canaccord Adams Inc. are acting as co-managersfor the offering.

A registration statement relating to these securities has been filed withthe Securities and Exchange Commission and has become effective. This pressrelease shall not constitute an offer to sell or the solicitation of an offerto buy, nor shall there be any sale of these securities in any state orjurisdiction in which such offer, solicitation or sale would be unlawful priorto registration or qualification under the securities laws of any such stateor jurisdiction. Any offer or sale will be made only by means of the writtenprospectus forming part of the effective registration statement.

A copy of the prospectus relating to the offering may be obtained bycontacting one of the following:

About Insulet Corporation

Insulet Corporation is an innovative medical device company dedicated toimproving the lives of people with diabetes. The Company's OmniPod InsulinManagement System is a revolutionary, discreet and easy-to-use insulininfusion system that features two easy-to-use parts with no tubing and fully-automated cannula insertion. Through the OmniPod System, Insulet seeks toexpand the use of continuous subcutaneous insulin infusion (CSII) therapyamong people with insulin-dependent diabetes. Founded in 2000, Insulet isbased in Bedford, MA.

For more information about Insulet Corporation and the OmniPod System,please visit our website at Morgan Securities Inc., National Statement Processing, Prospectus Library, 4 Chase Metrotech Center, CS Level, Brooklyn, NY 11245 or by calling (718) 242-8002. Merrill Lynch, Pierce, Fenner & Smith Incorporated, World Financial Center, 250 Vesey Street, New York, NY 10080 or by calling (212) 449-1000.

SOURCE Insulet Corporation


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
L'Oreal Paris Presents 'A Night of Hope' in Celebr...
Linnartz New Head of Investor Relations of Gerresh...